key: cord-0075046-7q40i1jl authors: White, Nicholas J; Day, Nicholas P J; Ashley, Elizabeth A; Smithuis, Frank M; Nosten, Francois H title: Have we really failed to roll back malaria? date: 2022-02-24 journal: Lancet DOI: 10.1016/s0140-6736(22)00175-1 sha: 763f2e0d5756af577fe23deba2723f674b59e586 doc_id: 75046 cord_uid: 7q40i1jl nan Immunosuppression defined as previously 1 . Age is shown as mean (standard deviation). We are performing a cohort study of 1,200 IC-HD patients across the UK 2 . The study has several objectives: 1. Confirm the immunogenicity of BNT162b2 and AZD1222 in IC-HD patients, including the generation of neutralising antibodies. a. Confirm augmentation of the antibody response with the second dose of vaccine b. Assess the longevity of the antibody response, including neutralising antibody. and AZD1222 IC-HD recipients. 3. Compare the profiles of neutralising antibodies generated by either vaccine between different age groups, different genders, different ethnicities, and different primary renal diseases. 4. Compare the profiles of neutralising antibodies generated between patients with and without diabetes or with and without immunosuppression. 5. Exploratory / discovery phase, where novel patterns / correlations are identified to provide hypothesis for testing in other cohorts / specifically targeted studies. For any cohort comparison we expect, given the nature of the UK's IC-HD population (its ethnicities, the frequencies of diabetes, immunosuppression) to be able to assemble groups of >100 patients for each comparison. We planned serum collections were before vaccination, 28 days after each vaccination, and 6 & 12 months after commencing vaccination. The study design is pragmatic and serum collection dates are reviewed in light of changing vaccination policy. Two haemodialysis centres are used in this report. In centre haemodialysis patients were included if they were able to consent into their local study and were clinically All serum samples were collected during routine IC-HD sessions from the HD circuit, without additional venepuncture. Sera were separated from blood in local laboratories and stored frozen. Sera were shipped to the Crick on dry ice, and barcoded whilst frozen. All live-virus microneutralisation were performed as described previously 3 . The SARS-CoV-2 B. Data analysis was performed in R4.0.4/Rstudio. Anonymised data wrangling used a mix of base R and tidyverse. As previously 2-4 , IC50 values above the quantitative limit of detection of the assay (>2560) were re-coded as 5120; IC50 values below the quantitative limit of the assay (< 40) but within the qualitative range were re-coded as 10 and data below the qualitative range (i.e. no response observed) were re-coded as 5. The resulting IC50 values are winsorized (40-2560). To assess responses to third doses in either AZD-AZD-BNT or BNT-BNT-BNT groups, McNemar's c 2 test was performed on 2x2 contingency tables, where columns were categorised nAbT (<40 or >40) before dose 3, and rows were categorised nAbT (<40 or >40) after dose FC011104, FC011233, FC001030, FC001159, FC001827, FC001078, FC001099, FC001169] and funded by the MRC [MRC-Pandemic Award-PRJ-20009 to RB, EJC] and Kidney Research UK [SP/VACCINE/2021 to MW, SM, EJC & RB], with KRUK supported by the NKF, the PKD charity, Kidney Wales and several Kidney Patient Associations Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients Haemodialysis COVID-19 consortium Sian Griffins 15 We thank the patients, their families, and the dialysis and renal unit staff who have delivered this at the frontline of a fast-moving pandemic, and the responsive rapid funding from Kidney Research UK and partners.